Ask AI
ProCE Banner Series

Novel ADC Therapies for Relapsed/Refractory Large B-Cell Lymphoma: Translating the Latest Advances Into Community Oncology Practice

This expert-led educational program provides insights into continuing education on the incorporation of antibody–drug conjugates in patients with relapsed or refractory diffuse large B-cell lymphoma.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is intended for community teams caring for patients with diffuse large B-cell lymphoma including hematologists/oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

All Events

Novel ADC Therapies for Relapsed/Refractory Large B-Cell Lymphoma: Translating the Latest Advances Into Community Oncology Practice

Upcoming Events

March

10

2026

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Simulcast | Host Group MI, Royal Oak, Michigan

Topics

Lymphomas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This certified educational activity aims to enhance clinical decision-making for R/R DLBCL, ensuring that treatment plans for relapsed patients reflect the latest evidence and genuinely align with each patient’s needs and values. By improving multidisciplinary providers' knowledge, competence, and coordination, the program seeks to improve patient outcomes (higher remission rates, improved quality of life) and patient satisfaction with their care.

Target Audience
This activity is intended for community teams caring for patients with diffuse large B-cell lymphoma including hematologists/oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify the potential of novel antibody-drug conjugates to address unmet needs for patients with R/R DLBCL

  • Develop individualized treatment protocols for patients with R/R DLBCL based on the latest clinical data, guidelines, and patient-specific factors

  • Formulate multidisciplinary strategies to identify, prevent, and manage toxicities associated with antibody-drug conjugates for R/R DLBCL

  • Incorporate patient goals and preferences into shared decision-making to optimize R/R DLBCL treatment planning across the continuum of care

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each event 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191